AerSale : 10-QHTMLPDFXBRL Zip Q2 2026

About this update from Aersale Corporation

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this report, including, without limitation, statements under the section "Management's Discussion and Analysis of Financial Condition and Results of Operations," are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements often may include words such as "anticipate," "estimate," "expect," "project," "plan," "intend," "believe," "may," "will," "should," "can have," "likely" and other words and terms of similar meaning. These statements are based upon management's current expectations, assumptions and estimates and are not guarantees of the timing or nature of our future operating or financial performance or other events. All forward-looking statements are subject to risks, uncertainties and other factors that may cause our actual results to differ materially from those that we expected, including: •The level of our customers' spending on and demand for TriLink and Cygnus products and services. •Our operating results are prone to significant fluctuation, which may make our future operating results difficult to predict and could cause our actual operating results to fall below expectations or any guidance we may provide. •Uncertainty regarding the extent and duration of our revenue associated with high-volume sales of CleanCap® for commercial phase vaccine programs and the dependency of such revenue, in important respects, on factors outside our control. •Shifts in the trade, economic and other policies and priorities of the U.S. federal government, on our and our customers' current and future business operations. •Unintended consequences from our recent organizational changes and workforce reduction. •Use of our products by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment, and the impact of unforeseen adverse events, negative clinical outcomes, development of alternative therapies, or increased regulatory scrutiny of these modes of treatment and their financial cost on our customers' use of our products and services. •Competition with life science, pharmaceutical and biotechnology companies who are substantially larger than us and potentially capable of developing new approaches that could make our products, services and technology obsolete. •The potential failure of our products and services to perform as expected and the reliability of the technology on which our products and services are based. •Our use of Artificial Intelligence technologies, including Machine Learning, and business, compliance, and reputational challenges that may result from such use. •The risk that our products do not comply with required quality standards. •Market acceptance of our life science reagents. •Our ability to efficiently manage our strategic acquisitions and organic growth opportunities. •Natural disasters, geopolitical instability (including ongoing military conflicts) and other catastrophic events. •Risks related to our acquisitions, including whether we achieve the anticipated benefits of acquisitions of businesses or technologies. •Product liability lawsuits. •Our dependency on a limited number of customers for a high percentage of our revenue and our ability to maintain our current relationships with such customers. •Our reliance on a limited number of suppliers or, in some cases, sole suppliers, for some of our raw materials and the risk that we may not be able to find replacements or immediately transition to alternative suppliers. •The risk that our products become subject to more onerous regulation by the U.S. Food and Drug Administration or other regulatory agencies in the future. •Our ability to obtain, maintain and enforce sufficient intellectual property protection for our current or future products. •The risk that a future cyber-attack or security breach cannot be prevented. •Our ability to protect the confidentiality of our proprietary information. •The risk that one of our products may be alleged (or found) to infringe on the intellectual property rights of third parties. •Compliance with our obligations under intellectual property license agreements. •Our or our licensors' failure to maintain the patents or patent applications in-licensed from a third party. 3 Table of Contents •Our ability to adequately protect our intellectual property and proprietary rights throughout the world. •Our existing level of indebtedness and our ability to raise additional capital on favorable terms. •Our ability to generate sufficient cash flow to service all of our indebtedness. •Our potential failure to meet our debt service obligations. •Restrictions on our current and future operations under the terms applicable to our credit agreement. •Our dependence, by virtue of our principal asset being our interest in Maravai Topco Holdings, LLC ("Topco LLC"), on distributions from Topco LLC to pay our taxes and expenses, including payments under a tax receivable agreement with the former owners of Topco LLC (the "Tax Receivable Agreement" or "TRA") together with various limitations and restrictions that impact Topco LLC's ability to make such distributions. •The risk that conflicts of interest could arise between our shareholders and Maravai Life Sciences Holdings, LLC ("MLSH 1"), the only other member of Topco LLC, and impede business decisions that could benefit our shareholders. •The substantial future cash payments we may be required to make under the Tax Receivable Agreement to MLSH 1 and Maravai Life Sciences Holdings 2, LLC ("MLSH 2"), an entity through which certain of our former owners hold their interests in the Company and the negative effect of such payments. •The fact that our organizational structure, including the TRA, confers certain benefits upon MLSH 1 and MLSH 2 that will not benefit our other common shareholders to the same extent as they will benefit MLSH 1 and MLSH 2. •Our ability to realize all or a portion of the tax benefits that are expected to result from the tax attributes covered by the Tax Receivable Agreement. •The possibility that we will receive distributions from Topco LLC significantly in excess of our tax liabilities and obligations to make payments under the Tax Receivable Agreement. •Factors that could lead to future impairment of our goodwill and other amortizable intangible assets. •Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns. •Our ability to design and maintain effective internal control over financial reporting in the future. •The fact that investment entities affiliated with GTCR, LLC ("GTCR") currently control a majority of the voting power of our outstanding common stock and may have interests that conflict with ours or yours in the future. •Risks related to our "controlled company" status within the meaning of the corporate governance standards of NASDAQ. •The potential anti-takeover effects of certain provisions in our corporate organizational documents. •Potential sales of a significant portion of our outstanding shares of Class A common stock. •Potential preferred stock issuances and the anti-takeover impacts of any such issuances. We derive many of our forward-looking statements from our operating budgets and forecasts, which are based on many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause our actual results to differ materially from our expectations or cautionary statements are disclosed under the sections entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025 and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. 4 Table of Contents Part I. Item 1. Financial Statements MARAVAI LIFESCIENCES HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par value) (Unaudited) June 30, 2026 December 31, 2025 Assets Current assets: Cash and cash equivalents $ 70,091 $ 216,890 Accounts receivable, net 31,138 25,498 Inventory 41,230 40,495 Prepaid expenses and other current assets 13,196 13,368 Total current assets 155,655 296,251 Property and equipment, net 142,414 151,479 Goodwill 129,429 129,429 Intangible assets, net 138,375 151,543 Other assets 37,873 41,875 Total assets $ 603,746 $ 770,577 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 7,125 $ 2,910 Accrued expenses and other current liabilities 30,169 36,567 Current portion of long-term debt 1,125 5,440 Total current liabilities 38,419 44,917 Long-term debt, less current portion 145,980 286,331 Finance lease liabilities, less current portion 29,591 30,141 Other long-term liabilities 34,168 36,477 Total liabilities 248,158 397,866 Commitments and contingencies (Note 5) Stockholders' equity: Class A common stock, $0.01 par value - 500,000 shares authorized; 148,888 and 145,324 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively 1,489 1,453 Class B common stock, $0.01 par value - 256,856 shares authorized; 110,684 issued and outstanding as of June 30, 2026 and December 31, 2025 1,107 1,107 Additional paid-in capital 207,598 199,177 Retained earnings (accumulated deficit) (6,031) 10,118 Accumulated other comprehensive income 459 524 Total stockholders' equity attributable to Maravai LifeSciences Holdings, Inc. 204,622 212,379 Non-controlling interest 150,966 160,332 Total stockholders' equity 355,588 372,711 Total liabilities and stockholders' equity $ 603,746 $ 770,577 The accompanying notes are an integral part of these condensed consolidated financial statements. 5 Table of Contents MARAVAI LIFESCIENCES HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenue $ 51,442 $ 47,397 $ 117,279 $ 94,247 Cost of revenue 30,792 39,629 62,928 78,754 Gross profit 20,650 7,768 54,351 15,493 Operating expenses: Selling, general and administrative 32,070 38,715 61,162 78,279 Research and development 3,702 4,882 7,591 9,770 Goodwill impairment - 30,449 - 42,884 Restructuring (33) - 2,845 - Total operating expenses 35,739 74,046 71,598 130,933 Loss from operations (15,089) (66,278) (17,247) (115,440) Other income (expense): Interest expense (4,809) (6,815) (10,558) (13,593) Interest income 1,159 3,030 3,032 6,255 Loss on extinguishment of debt (3,011) - (3,413) - Other expense (52) (4,062) (144) (4,038) Loss before income taxes (21,802) (74,125) (28,330) (126,816) Income tax benefit (171) (4,288) (322) (4,126) Net loss (21,631) (69,837) (28,008) (122,690) Net loss attributable to non-controlling interests (9,215) (30,246) (11,859) (53,154) Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (12,416) $ (39,591) $ (16,149) $ (69,536) Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted $ (0.08) $ (0.27) $ (0.11) $ (0.48) Weighted average number of Class A common shares outstanding, basic and diluted 147,996 144,236 147,215 143,833 The accompanying notes are an integral part of these condensed consolidated financial statements. 6 Table of Contents MARAVAI LIFESCIENCES HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (in thousands) (Unaudited) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net loss $ (21,631) $ (69,837) $ (28,008) $ (122,690) Other comprehensive income (loss): Foreign currency translation adjustments (12) 442 (114) 1,016 Total other comprehensive income (loss) (12) 442 (114) 1,016 Total comprehensive loss (21,643) (69,395) (28,122) (121,674) Comprehensive loss attributable to non-controlling interests (9,220) (30,054) (11,908) (52,712) Total comprehensive loss attributable to Maravai LifeSciences Holdings, Inc. $ (12,423) $ (39,341) $ (16,214) $ (68,962) The accompanying notes are an integral part of the condensed consolidated financial statements. 7 Table of Contents MARAVAI LIFESCIENCES HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (in thousands) (Unaudited) Three Months Ended June 30, 2026 Class A Common Stock Class B Common Stock Shares Amount Shares Amount Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income Non-Controlling Interest Total Stockholders' Equity March 31, 2026 147,496 $ 1,475 110,684 $ 1,107 $ 202,131 $ 6,385 $ 466 $ 157,519 $ 369,083 Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes 1,392 14 - - (2,071) - - - (2,057) Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC - - - - 1,699 - - (1,699) - Stock-based compensation - - - - 5,839 - - 4,366 10,205 Net loss - - - - - (12,416) - (9,215) (21,631) Foreign currency translation adjustment - - - - - - (7) (5) (12) June 30, 2026 148,888 $ 1,489 110,684 $ 1,107 $ 207,598 $ (6,031) $ 459 $ 150,966 $ 355,588 Six Months Ended June 30, 2026 Class A Common Stock Class B Common Stock Shares Amount Shares Amount Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income Non-Controlling Interest Total Stockholders' Equity December 31, 2025 145,324 $ 1,453 110,684 $ 1,107 $ 199,177 $ 10,118 $ 524 $ 160,332 $ 372,711 Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes 3,564 36 - - (5,985) - - - (5,949) Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC - - - - 4,726 - - (4,726) - Stock-based compensation - - - - 9,680 - - 7,268 16,948 Net loss - - - - - (16,149) - (11,859) (28,008) Foreign currency translation adjustment - - - - - - (65) (49) (114) June 30, 2026 148,888 $ 1,489 110,684 $ 1,107 $ 207,598 $ (6,031) $ 459 $ 150,966 $ 355,588 Three Months Ended June 30, 2025 Class A Common Stock Class B Common Stock Shares Amount Shares Amount Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income Non-Controlling Interest Total Stockholders' Equity March 31, 2025 143,958 $ 1,440 110,684 $ 1,107 $ 186,797 $ 110,946 $ 324 $ 229,659 $ 530,273 Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes 657 6 - - 310 - - - 316 Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC - - - - 427 - - (427) - Stock-based compensation - - - - 3,843 - - 2,946 6,789 Net loss - - - - - (39,591) - (30,246) (69,837) Foreign currency translation adjustment - - - - - - 250 192 442 June 30, 2025 144,615 $ 1,446 110,684 $ 1,107 $ 191,377 $ 71,355 $ 574 $ 202,124 $ 467,983 8 Table of Contents Six Months Ended June 30, 2025 Class A Common Stock Class B Common Stock Shares Amount Shares Amount Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Accumulated Other Comprehensive Income Non-Controlling Interest Total Stockholders' Equity December 31, 2024 141,976 $ 1,420 110,684 $ 1,107 $ 181,874 $ 140,891 $ - $ 251,917 $ 577,209 Issuance of Class A common stock under employee equity plans, net of shares withheld for employee taxes 2,639 26 - - (4,770) - - - (4,744) Non-controlling interest adjustment for changes in proportionate ownership in Topco LLC - - - - 4,558 - - (4,558) - Stock-based compensation - - - - 9,715 - - 7,477 17,192 Net loss - - - - - (69,536) - (53,154) (122,690) Foreign currency translation adjustment - - - - - - 574 442 1,016 June 30, 2025 144,615 $ 1,446 110,684 $ 1,107 $ 191,377 $ 71,355 $ 574 $ 202,124 $ 467,983 The accompanying notes are an integral part of the condensed consolidated financial statements. 9 Table of Contents MARAVAI LIFESCIENCES HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (Unaudited) Six Months Ended June 30, 2026 2025 Operating activities: Net loss $ (28,008) $ (122,690) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation 10,213 11,650 Amortization of intangible assets 12,941 14,230 Amortization of operating lease right-of-use assets 3,231 4,416 Stock-based compensation expense 16,948 17,192 Loss on extinguishment of debt 3,413 - Impairment 469 43,936 Acquisition related tax adjustment - 4,082 Other 201 897 Changes in operating assets and liabilities, net of acquisitions: Accounts receivable (5,626) 10,661 Inventory (735) 3,557 Prepaid expenses and other current assets 662 (621) Accounts payable 4,362 1,074 Accrued expenses and other current liabilities (3,521) 6,639 Other long-term liabilities (1,893) (14,678) Net cash provided by (used in) operating activities 12,657 (19,655) Investing activities: Cash paid for acquisitions of a business, net of cash acquired - (18,990) Purchases of property and equipment (4,807) (7,375) Net cash used in investing activities (4,807) (26,365) Financing activities: Proceeds from borrowings of long-term debt 150,000 - Principal repayments of long-term debt (294,240) (2,720) Financing costs incurred for long-term debt (3,575) - Taxes paid for shares withheld under employee equity plans, net of proceeds from issuance of Class A common stock (5,936) (4,719) Other financing activities, net (455) 1,005 Net cash used in financing activities (154,206) (6,434) Effects of exchange rate changes on cash and cash equivalents 47 (38) Net decrease in cash, cash equivalents, and restricted cash (146,309) (52,492) Cash and cash equivalents, beginning of period 216,890 322,399 Cash, cash equivalents and restricted cash, end of period $ 70,581 $ 269,907 Supplemental cash flow information: Cash paid for interest $ 13,740 $ 12,637 Cash refunded for income taxes, net $ - $ (535) Supplemental disclosures of non-cash activities: Property and equipment included in accounts payable and accrued expenses $ 539 $ 1,722 Right-of-use assets obtained in exchange for operating lease liabilities $ - $ 463 10 Table of Contents Six Months Ended June 30, 2026 2025 Fair value of contingent consideration liability recorded in connection with acquisition of a business $ - $ 4,800 Accrued consideration payable recorded in connection with acquisitions of a business $ - $ 2,331 As of June 30, Reconciliation of cash, cash equivalents and restricted cash reported in the condensed consolidated balance sheets: 2026 2025 Cash and cash equivalents $ 70,091 $ 269,907 Restricted cash included in other current assets 490 - Total cash, cash equivalents, and restricted cash $ 70,581 $ 269,907 The accompanying notes are an integral part of the condensed consolidated financial statements. 11 Table of Contents MARAVAI LIFESCIENCES HOLDINGS, INC. NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1.Organization and Significant Accounting Policies Description of Business Maravai LifeSciences Holdings, Inc. (the "Company," and together with its consolidated subsidiaries, "Maravai," "we," "us," and "our") provides critical products to enable the development of drugs, therapeutics, diagnostics, vaccines and to support research on human diseases. Our products address the key phases of biopharmaceutical development and include complex nucleic acids for therapeutic and diagnostic applications and immunoassay, qPCR and mass spectrometry-based products and services to detect impurities during the production of biopharmaceutical products. The Company is headquartered in San Diego, California and operates in two principal businesses: TriLink and Cygnus. Our TriLink business manufactures and sells products used in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid ("DNA") and ribonucleic acid ("RNA"). Our core TriLink offerings include messenger ribonucleic acid ("mRNA"), our proprietary CleanCap® capping and ModTail™ poly(A) tail modification technologies, long and short oligonucleotides, our oligonucleotide building blocks, and custom enzyme development and manufacturing. Our Cygnus business sells biologic safety testing products and highly specialized analytical products for use in biologic manufacturing process development, including custom product-specific antibody and assay development services. Basis of Presentation The Company is a holding company and has no material assets other than our ownership of equity interests in Topco LLC. As the sole managing member of Topco LLC, the Company operates and controls all of the business and affairs, and is the ultimate parent company, of Topco LLC. The Company conducts its business through Topco LLC and its consolidated subsidiaries. MLSH 1, which is controlled by investment entities affiliated with GTCR, is the only other member of Topco LLC that is not a wholly-owned subsidiary of the Company. Because we manage and operate the business and control the strategic decisions and day-to-day operations of Topco LLC, and also have a substantial financial interest in Topco LLC, we consolidate the financial results of Topco LLC, and a portion of our net loss is allocated to the non-controlling interests in Topco LLC held by MLSH 1. The accompanying unaudited interim condensed consolidated financial statements include the accounts of the Company and its subsidiaries, with all intercompany accounts and transactions eliminated. Certain prior period information has been reclassified to conform to the current period presentation. Unaudited Interim Condensed Consolidated Financial Statements The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and pursuant to Form 10-Q of Regulation S-X of the Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements include all adjustments necessary to fairly state our financial position and the results of our operations and cash flows for interim periods in accordance with GAAP. All such adjustments are of a normal, recurring nature. Operating results for the three and six months ended June 30, 2026 are not necessarily indicative of the results that may be expected for the full year ending December 31, 2026 or for any future period. The condensed consolidated balance sheet presented as of December 31, 2025 has been derived from the audited consolidated financial statements as of that date. The condensed consolidated financial statements and notes are presented as permitted by Form 10-Q and do not contain all information that is included in the annual consolidated financial statements and notes thereto of the Company. The condensed consolidated financial statements and notes included in this report should be read in conjunction with the consolidated financial statements and notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 ("2025 Form 10-K") filed with the SEC. Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenue, expenses, and related disclosures. These estimates form the basis for judgments the Company makes about the carrying values of assets and liabilities that are not readily apparent from other sources. The Company bases its estimates and judgments on historical experience and on various other assumptions that the Company believes are reasonable under the circumstances. These estimates are based on 12 Table of Contents management's knowledge about current events and expectations about actions the Company may undertake in the future. Significant estimates include, but are not limited to, the payable to related parties pursuant to the Tax Receivable Agreement (as defined in Note 9), the realizability of our net deferred tax assets, valuation of goodwill and long-lived assets, and valuation of assets acquired and liabilities assumed in business combinations. Actual results could differ materially from those estimates. Significant Accounting Policies A description of the Company's significant accounting policies is included in Note 1 of the Notes to the Consolidated Financial Statements included in the 2025 Form 10-K. There were no material changes in the Company's significant accounting policies during the three and six months ended June 30, 2026. Revenue Recognition Contract balances Contract liabilities include billings in excess of revenue recognized, such as customer deposits and deferred revenue, which are both included in accrued expenses and other current liabilities on the accompanying condensed consolidated balance sheets. Customer deposits are recorded when cash payments are received or due in advance of performance. Deferred revenue is recorded when the Company has unsatisfied performance obligations. Total contract liabilities were $5.4 million and $3.0 million as of June 30, 2026 and December 31, 2025, respectively. Contract liabilities are generally expected to be recognized into revenue within the next twelve months. During the three and six months ended June 30, 2026, the Company recognized revenue of $0.8 million and $1.5 million, respectively, that was included in the contract liabilities balances as of December 31, 2025. During the three and six months ended June 30, 2025, the Company recognized revenue of $0.6 million and $1.5 million, respectively, that was included in the contract liabilities balances as of December 31, 2024. Disaggregation of revenue The following tables summarize revenue by segment and region for the periods presented (in thousands): Three Months Ended June 30, 2026 TriLink Cygnus Total North America $ 24,646 $ 6,638 $ 31,284 Europe, the Middle East and Africa 6,129 4,324 10,453 Asia Pacific 3,701 5,618 9,319 Latin and Central America 193 193 386 Total revenue $ 34,669 $ 16,773 $ 51,442 Six Months Ended June 30, 2026 TriLink Cygnus Total North America $ 52,599 $ 14,374 $ 66,973 Europe, the Middle East and Africa 23,660 8,740 32,400 Asia Pacific 5,610 11,581 17,191 Latin and Central America 276 439 715 Total revenue $ 82,145 $ 35,134 $ 117,279 13 Table of Contents Three Months Ended June 30, 2025 TriLink Cygnus Total North America $ 23,872 $ 6,767 $ 30,639 Europe, the Middle East and Africa 4,107 4,288 8,395 Asia Pacific 3,023 5,135 8,158 Latin and Central America 83 122 205 Total revenue $ 31,085 $ 16,312 $ 47,397 Six Months Ended June 30, 2025 TriLink Cygnus Total North America $ 45,846 $ 14,062 $ 59,908 Europe, the Middle East and Africa 6,701 8,572 15,273 Asia Pacific 7,170 11,545 18,715 Latin and Central America 118 233 351 Total revenue $ 59,835 $ 34,412 $ 94,247 Revenue attributed to United States customers was $30.9 million and $66.1 million for the three and six months ended June 30, 2026, respectively. Revenue attributed to United States customers was $30.3 million and $59.1 million for the three and six months ended June 30, 2025, respectively. Total revenue is attributed to geographic regions based on the country in which the customers are located or the bill-to location of the transaction. Non-Controlling Interests Non-controlling interests represent the portion of profit or loss, net assets and comprehensive income or loss of our consolidated subsidiaries that is not allocable to the Company based on our percentage of ownership of such entities. We are the sole managing member of Topco LLC. As of June 30, 2026, we held approximately 57.4% of the outstanding LLC units of Topco LLC ("LLC Units"), and MLSH 1 held approximately 42.6% of the outstanding LLC Units. Therefore, we report non-controlling interests based on the percentage of LLC Units held by MLSH 1 on the condensed consolidated balance sheet as of June 30, 2026. Income or loss attributed to the non-controlling interest in Topco LLC is based on the LLC Units outstanding during the period for which the income or loss is generated and is presented on the condensed consolidated statements of operations and condensed consolidated statements of comprehensive loss. MLSH 1 is entitled to exchange its LLC Units, together with an equal number of shares of our Class B common stock (together referred to as "Paired Interests"), for shares of our Class A common stock on a one-for-one basis or, at our election, for cash, from a substantially concurrent public offering or private sale (based on the price of our Class A common stock in such public offering or private sale). As such, future exchanges of Paired Interests by MLSH 1 will result in a change in ownership and reduce or increase the amount recorded as non-controlling interests and increase or decrease additional paid-in-capital when Topco LLC has positive or negative net assets, respectively. Payments pursuant to Topco LLC Operating Agreement Topco LLC is subject to an operating agreement (the "LLC Operating Agreement") that was put in place at the date of a series of organizational transactions (the "Organizational Transactions") effected immediately prior to our initial public offering (the "IPO"). The LLC Operating Agreement includes a provision requiring cash distributions enabling Topco's unit holders, including MLSH 1, to pay their taxes on income passing through from Topco LLC. No such cash distributions were made to MLSH 1 during the three and six months ended June 30, 2026 and 2025. Stock-Based Compensation The Company recognizes stock-based compensation for all equity awards made to employees, non-employee directors and contractors based upon the awards' estimated grant date fair value, including stock options, restricted stock units and performance stock units ("PSUs"). For PSUs with performance conditions, expense is recognized based on the Company's current estimate of achievement and may be adjusted or reversed if the performance condition is not met. The fair value of PSUs with performance conditions is based on the closing market price of the Company's common stock on the date of grant. During the six months ended June 30, 2026, the Company granted PSUs to employees that vest over a three-year service period and are subject to a performance condition. There were no PSUs with performance conditions granted during the three months 14 Table of Contents ended June 30, 2026. Compensation expense for these awards is recognized when it is probable that the performance condition will be achieved, and over the requisite service period based on the Company's current estimate of expected payout. As of June 30, 2026, the unrecognized compensation cost was $23.4 million, which is expected to be recognized over approximately 2.75 years. During the three and six months ended June 30, 2025, the Company did not have any such PSUs. Fair Value of Financial Instruments The Company defines fair value as the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. The Company follows accounting guidance that has a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of the asset or liability as of the measurement date. Instruments with readily available actively quoted prices, or for which fair value can be measured from actively quoted prices in an orderly market, will generally have a higher degree of market price transparency and a lesser degree of judgment used in measuring fair value. The three levels of the hierarchy are defined as follows: Level 1-Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets; Level 2-Include other inputs that are directly or indirectly observable in the marketplace; and Level 3-Unobservable inputs which are supported by little or no market activity. As of June 30, 2026 and December 31, 2025, the fair values of cash and cash equivalents, trade accounts receivable, net, and trade accounts payable, approximated their carrying amounts due to the short maturities of these instruments. The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. Cash and cash equivalents consist of deposits held at financial institutions and money market funds. As of June 30, 2026 and December 31, 2025, the fair value of the Company's long-term debt approximated its carrying value, excluding the effect of unamortized debt discount, as it is based on borrowing rates currently available to the Company for debt with similar terms and maturities (Level 2 inputs). The following tables summarize the Company's financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy as of the periods presented (in thousands): Fair Value Measurements as of June 30, 2026 Line Item in the Condensed Consolidated Balance Sheets Level 1 Level 2 Level 3 Total Assets Money market funds Cash and cash equivalents $ 69,165 $ - $ - $ 69,165 Fair Value Measurements as of December 31, 2025 Line Item in the Condensed Consolidated Balance Sheets Level 1 Level 2 Level 3 Total Assets Money market funds Cash and cash equivalents $ 216,384 $ - $ - $ 216,384 Concentration of Credit Risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains the majority of its cash balances at multiple financial institutions that management believes are of high-credit-quality and financially stable. Cash is deposited with major financial institutions in excess of Federal Deposit Insurance Corporation insurance limits. The Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held. The Company provides credit, in the normal course of business, to international and domestic distributors as well as certain customers, which are geographically dispersed. The Company attempts to limit its credit risk by performing ongoing credit evaluations of its customers and maintaining adequate allowances for potential credit losses. 15 Table of Contents The following table summarizes revenue from each of our customers who individually accounted for 10% or more of our total revenue or accounts receivable for the periods presented: Revenue Accounts Receivable, net Three Months Ended June 30, Six Months Ended June 30, June 30, 2026 December 31, 2025 2026 2025 2026 2025 Pfizer, Inc. * * 12.2 % * * * Nacalai USA, Inc. * * * * * 12.0 % Seqirus Inc. * * * * 18.3 % * ____________________ *Less than 10% For the three and six months ended June 30, 2026, substantially all of the revenue recorded for Pfizer, Inc. was generated by the TriLink segment. Recently Issued Accounting Pronouncements Not Yet Adopted In November 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40) - Disaggregation of Income Statement Expenses ("ASU 2024-03"). This ASU amends existing income statement disclosure guidance, primarily requiring more detailed disclosure for expenses. ASU 2024-03 is effective for the Company for annual periods beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The amendments can be applied on either a prospective basis or retrospective basis. The Company is currently evaluating the impact of adopting this standard on its consolidated financial statements and disclosures. 2.Acquisitions Molecular Assemblies On January 23, 2025, the Company completed the acquisition of assets from Molecular Assemblies, Inc. ("Molecular") for a total purchase consideration of $11.2 million. Pursuant to the Molecular Assemblies Asset Purchase Agreement (the "Molecular APA"), the Company maintained an indemnity and adjustment holdback of $2.0 million for the purpose of providing security against any adjustments to the amounts at closing. The indemnity holdback period extended to the later of six months from the closing date or when Molecular met certain conditions, as defined in the Molecular APA, related to the wind down of Molecular. The indemnity holdback period expired during the third quarter of 2025, and consequently, the $2.0 million holdback amount was fully paid to the Molecular sellers. Revenue and earnings from the assets acquired from Molecular included in the Company's condensed consolidated statements of operations since the date of acquisition were immaterial. No pro forma revenue or earnings information for the three and six months ended June 30, 2026 and 2025 has been presented as the impact was determined not to be material to the Company's condensed consolidated revenue and net loss for the respective periods. Officinae Bio On February 21, 2025, the Company completed the acquisition of the DNA and RNA business of Officinae Bio ("Officinae") for a total purchase consideration of $15.1 million. Pursuant to the Officinae Securities Purchase Agreement (the "Officinae SPA") between the Company and sellers of Officinae, additional payments to the sellers of Officinae are dependent upon certain milestones and meeting or exceeding defined revenue targets through December 31, 2028 (the "Officinae Contingent Consideration"). The Officinae SPA provides for a total maximum Officinae Contingent Consideration of $35.0 million, with $5.0 million of such contingent consideration payable in cash upon the achievement of a certain integration milestone (the "Milestone Consideration") and up to an additional $30.0 million payable in a mix of cash and shares of the Company's Class A common stock, such mix to be mutually agreed at the time of any payout, upon the achievement of certain revenue and license milestones (the "Earnout Considerations"). The Milestone Consideration was recorded as contingent consideration and was included as part of the purchase consideration. 16 Table of Contents During the third quarter of 2025, the Company determined the conditions for payment were satisfied and paid the Milestone Consideration amount of $5.0 million to the sellers of Officinae. The Earnout Considerations had no probability of achievement and the fair value at the acquisition date and at June 30, 2026 could not be reasonably estimated. Revenue and earnings from Officinae included in the Company's condensed consolidated statements of operations since the date of acquisition were immaterial. No pro forma revenue or earnings information for the three and six months ended June 30, 2026 and 2025 has been presented as the impact was determined not to be material to the Company's condensed consolidated revenue and net loss for the respective periods. 3.Restructuring In August 2025, the Company implemented a corporate realignment plan (the "2025 Corporate Realignment Plan") that included the termination of approximately 25% of the Company's workforce, a phased reduction of the Company's facilities footprint, and other actions designed to significantly reduce operating costs and focus our resources on projects that we believe will deliver sustainable long-term growth, including improving our e-commerce presence. The reduction in force was substantially completed as of November 4, 2025, following the end of the sixty-day notification period required by the Worker Adjustment and Retraining Notification Act (the "WARN Act"). The Company anticipates completion of the 2025 Corporate Realignment Plan by the end of the third quarter of 2026. For the three months ended June 30, 2026, restructuring charges were not significant. The Company's restructuring charges by segment and unallocated corporate costs, which are recorded as restructuring expenses on the condensed consolidated statements of operations, were as follows (in thousands): Six Months Ended June 30, 2026 Severance and Other Employee Costs (Benefit) Non-Employee Contract Costs Asset Impairments Professional Fees Total TriLink $ (422) $ 1,979 $ 422 $ - $ 1,979 Cygnus (3) - - - (3) Corporate (23) - - 892 869 Total $ (448) $ 1,979 $ 422 $ 892 $ 2,845 The following table summarizes the activity for accrued restructuring costs, which is recorded within accrued expenses and other current liabilities on the condensed consolidated balance sheets, as of the periods presented (in thousands): Severance and Other Employee Costs (Benefit) Non-Employee Contract Costs Asset Impairments Professional Fees Total Balance as of December 31, 2025 $ 2,042 $ - $ - $ 176 $ 2,218 Charges (benefit) (448) 1,979 422 892 2,845 Non-cash benefit (charges) 248 - (422) - (174) Cash payments (1,562) (300) - (998) (2,860) Balance as of June 30, 2026 $ 280 $ 1,679 $ - $ 70 $ 2,029 The Company is currently unable to reasonably estimate certain costs associated with the phased reduction of its facilities. Additional costs, which could be material, may be incurred as the Company implements and progresses through the phases of its restructuring plan. 17 Table of Contents 4.Balance Sheet Components Inventory Inventory consisted of the following as of the periods presented (in thousands): June 30, 2026 December 31, 2025 Raw materials $ 12,882 $ 14,606 Work-in-process 9,904 7,318 Finished goods 18,444 18,571 Total inventory $ 41,230 $ 40,495 5.Commitments and Contingencies Unconditional Purchase Obligations In the ordinary course of business, we enter into certain unconditional purchase obligations with our suppliers to purchase products and services. These purchase obligations are enforceable, legally binding agreements and specify terms that include provisions with respect to quantities, pricing and timing of purchases. Amounts purchased under these obligations were nominal and $0.3 million for the three and six months ended June 30, 2026. Amounts purchased under these obligations totaled $1.9 million and $3.0 million for the three and six months ended June 30, 2025. As of June 30, 2026, future minimum commitments under these obligations totaled $4.4 million, of which $0.4 million is scheduled to be spent within the next 12 months, and $4.0 million is scheduled to be spent between one and more than ten years in the future. Legal Proceedings In addition to the proceedings described below, the Company is involved in various legal proceedings arising in the normal course of business. The Company accrues for a loss contingency when it determines that it is probable, after consultation with counsel, that a liability has been incurred and the amount of such loss can be reasonably estimated. As of the date of this report, none of such loss contingencies, either individually or in the aggregate, are expected to have a material adverse effect on the Company's consolidated financial position, results of operations or cash flows. On March 3, 2025, a purported stockholder filed a putative class action lawsuit against the Company and certain former officers of the Company in the United States District Court for the Southern District of California, captioned Nelson v. Maravai Lifesciences Holdings, Inc., et al. (the "Securities Class Action"). The court dismissed the Securities Class Action with prejudice in February 2026, and entered judgment in favor of the Company and its former officers. On each of June 20, 2025, and July 16, 2025, separate purported stockholder derivative lawsuits were filed and later consolidated in the United States District Court for the Southern District of California for the benefit of the Company as the nominal defendant, captioned Mercer v. Martin, et al. and Husurianto v. Martin, et al., respectively (the "Derivative Actions"). Pursuant to a joint motion by the parties, the court dismissed the Derivative Actions without prejudice in March 2026. 6.Long-Term Debt 2026 Credit Agreement On June 2, 2026, Maravai Intermediate Holdings, LLC, a wholly-owned subsidiary of Maravai Topco Holdings, LLC, as borrower, entered into a new credit agreement (the "2026 Credit Agreement") with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The 2026 Credit Agreement provides for a $150.0 million initial term loan facility (the "2026 Term Loan") and a $30.0 million revolving credit facility (the "2026 Revolving Credit Facility"), each maturing on June 2, 2032. In connection with entering into the 2026 Credit Agreement, the Company repaid all amounts outstanding under its prior credit agreement, dated as of October 19, 2020 (the "Prior Credit Agreement"), and terminated the related term loan facility and revolving credit facility, including the related guarantees and security interests. In connection with the termination of the Prior Credit Agreement, the Company issued a cash-collateralized letter of credit of $0.5 million related to a lease, which is classified as restricted cash and is included in other current assets on the Condensed Consolidated Balance Sheet as of June 30, 2026, as the letter of credit is expected to expire within the next twelve months. 18 Table of Contents Borrowings under the 2026 Credit Agreement bear interest, at the Company's option, at either (i) the Term Secured Overnight Financing Rate ("Term SOFR") plus 5.00% per annum or (ii) an alternate base rate plus 4.00% per annum, with a 0.25% stepdown available for any period if the consolidated first lien net leverage ratio of the Borrower is equal to or less than 3.00 to 1.00. The Term SOFR is subject to a floor of 0.75%. From the effective date of the 2026 Credit Agreement until delivery of the first compliance certificate and related financial statements, the applicable margin is 5.00% per annum for Term SOFR borrowings and 4.00% per annum for alternate base rate borrowings. Thereafter, the applicable margin is based on the Company's senior secured first lien net leverage ratio and ranges from 4.75% to 5.00% per annum for Term SOFR borrowings and from 3.75% to 4.00% per annum for alternate base rate borrowings. Borrowings under the 2026 Credit Agreement are guaranteed by Maravai Topco Holdings, LLC and certain subsidiaries of the Company and are secured by a first-priority lien on substantially all assets of the borrower and the guarantors, in each case subject to customary exceptions. The 2026 Term Loan requires mandatory quarterly principal payments, commencing on December 31, 2026, in an aggregate principal amount equal to 0.25% of the aggregate principal amount of the 2026 Term Loan outstanding on the effective date, or $0.4 million per quarter, with the remaining balance due at maturity on June 2, 2032. Amounts repaid or prepaid under the 2026 Term Loan may not be reborrowed. The 2026 Term Loan includes prepayment provisions that allow the Company, at the Company's option, to repay all or a portion of the outstanding principal at any time, subject to a fee of 1.00% of the aggregate principal amount of the 2026 Term Loan if repaid prior to June 2, 2027, and no fee if on or after June 2, 2027. The 2026 Credit Agreement requires mandatory prepayments of the 2026 Term Loan under certain circumstances, including from certain asset sale, casualty and debt incurrence proceeds, subject to reinvestment rights and other exceptions. Commencing with the fiscal year ending December 31, 2027, the 2026 Credit Agreement also requires an annual excess cash flow prepayment equal to 50% of excess cash flow if the Company's senior secured first lien net leverage ratio is greater than 3.50:1.00, or 25% if the Company's senior secured first lien net leverage ratio is less than or equal to 3.50:1.00 and greater than 3.00:1.00. No excess cash flow prepayment is required for a fiscal year to the extent the calculated prepayment amount is equal to or less than the greater of $5.3 million and 15% of Consolidated EBITDA, as defined in the 2026 Credit Agreement. The 2026 Credit Agreement contains covenants that, among other things, limit the Company's ability to incur or prepay certain indebtedness, pay dividends or make other restricted payments, dispose of assets, engage in mergers and consolidations, make acquisitions and other investments, enter into certain affiliate transactions, create liens and make changes to the nature of the business. Commencing December 31, 2026, the 2026 Credit Agreement includes a financial performance covenant that requires the Company to maintain a senior secured first lien net leverage ratio not to exceed 6.50:1.00 if revolving exposure, excluding undrawn letters of credit, is equal to or greater than 40.0% of the aggregate revolving commitments. The Company was in compliance with the covenants under the 2026 Credit Agreement as of June 30, 2026. In connection with the repayment of all amounts outstanding under the Prior Credit Agreement and the termination of the Prior Credit Agreement, including the related term loan facility, revolving credit facility, related guarantees and security interests, the Company recorded losses on extinguishment of debt of $3.0 million and $3.4 million during the three and six months ended June 30, 2026, respectively, primarily related to the write-offs of unamortized debt issuance costs and original issue discount associated with the prior term loan, deferred financing costs related to the prior revolving credit facility, and related lender and legal fees. In connection with the 2026 Credit Agreement, the Company capitalized debt issuance costs and original issue discount of $2.9 million. Unamortized debt issuance costs and original issue discount related to the 2026 Term Loan are presented as a direct deduction from the carrying amount of long-term debt, while unamortized debt issuance costs related to the 2026 Revolving Credit Facility are recorded within other assets in the accompanying condensed consolidated balance sheet as of June 30, 2026. As of June 30, 2026, unamortized issuance costs related to the 2026 Revolving Credit Facility totaled $0.6 million and are included within other assets on the condensed consolidated balance sheet. The Company's long-term debt consisted of the following as of the periods presented (in thousands): June 30, 2026 December 31, 2025 Term Loan $ 150,000 $ 294,240 Less: unamortized debt discount and issuance costs (2,895) (2,469) Total long-term debt 147,105 291,771 Less: current portion (1,125) (5,440) Total long-term debt, less current portion $ 145,980 $ 286,331 19 Table of Contents There were no borrowings under the 2026 Revolving Credit Facility or the Prior Revolving Credit Facility as of June 30, 2026 and December 31, 2025, respectively. The Company is required to pay a commitment fee of 0.50% per annum on the daily average unused portion of the 2026 Revolving Credit Facility, payable quarterly. As of June 30, 2026, the aggregate future principal maturities of the Company's debt obligations based on contractual due dates were as follows (in thousands): 2026 (remaining six months) $ 375 2027 1,500 2028 1,500 2029 1,500 2030 1,500 2031 1,500 Thereafter 142,125 Total long-term debt $ 150,000 7.Net Loss Per Class A Common Share Attributable to Maravai LifeSciences Holdings, Inc. Basic net loss per Class A common share has been calculated by dividing net loss for the period, adjusted for net loss attributable to non-controlling interests, by the weighted average number of Class A common shares outstanding during the period. In periods in which the Company reports a net loss attributable to Maravai LifeSciences Holdings, Inc., diluted net loss per Class A common share attributable to the Company is the same as basic net loss per Class A common share attributable to the Company, since dilutive equity instruments are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to Maravai LifeSciences Holdings, Inc. during the three and six months ended June 30, 2026 and 2025. The following table presents the computation of basic and diluted net loss per Class A common share attributable to the Company for the periods presented (in thousands, except per share amounts): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Net loss $ (21,631) $ (69,837) $ (28,008) $ (122,690) Less: loss attributable to common non-controlling interests 9,215 30,246 11,859 53,154 Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (12,416) $ (39,591) $ (16,149) $ (69,536) Weighted average Class A common shares outstanding 147,996 144,236 147,215 143,833 Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted $ (0.08) $ (0.27) $ (0.11) $ (0.48) Shares of Class B common stock do not share in the earnings or losses of the Company and are therefore not participating securities. As such, a separate presentation of basic and diluted net loss per share for Class B common stock under the two-class method has not been presented. 20 Table of Contents The following table presents potentially dilutive securities excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive for the periods presented (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Restricted stock units 13,207 13,360 13,207 3,566 Performance-based incentive units 7,886 - 7,886 - Stock options 3,459 4,550 3,459 4,550 Shares estimated to be purchased under the employee stock purchase plan 1,076 2,025 1,006 2,025 Shares of Class B common stock 110,684 110,684 110,684 110,684 Total 136,312 130,619 136,242 120,825 Shares underlying contingently issuable awards that have not met the necessary conditions as of the end of a reporting period are not included in the calculation of diluted net loss per Class A common share attributable to the Company for that period. The Company had contingently issuable performance stock units outstanding that did not meet the market conditions as of June 30, 2026 and 2025 and, therefore, were excluded from the calculation of diluted net loss per Class A common share attributable to the Company. The maximum number of potentially dilutive shares that could be issued upon vesting for such awards was 3.3 million as of June 30, 2026 and 3.3 million as of June 30, 2025. These share amounts were excluded from the potentially dilutive securities in the table above. 8.Income Taxes The Company is subject to U.S. federal, state and foreign income taxes with respect to its allocable share of any taxable income or loss of Topco LLC, as well as any stand-alone income or loss we generate. Topco LLC is organized as a limited liability company and treated as a partnership for U.S. federal tax purposes and generally does not pay income taxes on its taxable income in most jurisdictions. Instead, Topco LLC's taxable income or loss is passed through to its members, including us. The following table summarizes the Company's income tax expense (benefit) and effective tax rate for the periods presented (in thousands, except percentages): Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Loss before income taxes $ (21,802) $ (74,125) $ (28,330) $ (126,816) Income tax benefit $ (171) $ (4,288) $ (322) $ (4,126) Effective tax rate 0.8 % 5.8 % 1.1 % 3.3 % The Company's effective tax rate of 0.8% and 1.1% for the three and six months ended June 30, 2026, respectively, differed from the U.S. federal statutory income tax rate of 21.0%, primarily due to loss associated with non-controlling interest and the valuation allowance recorded against the Company's deferred tax assets. The Company's effective tax rate of 5.8% and 3.3% for the three and six months ended June 30, 2025, respectively, differed from the U.S. federal statutory income tax rate of 21.0%, primarily due to loss associated with non-controlling interest, the valuation allowance recorded against the Company's deferred tax assets, and the release of a previous uncertain tax position due to statute of expiration. As of June 30, 2026 and December 31, 2025, the Company had $1.1 million and $1.0 million, respectively, of unrecognized tax benefits, all of which would affect the effective tax rate if recognized. The Company recognizes interest related to uncertain tax benefits as a component of income tax expense (benefit), which was immaterial during the three and six months ended June 30, 2026 and 2025. Tax Distributions to Topco LLC's Unit Holders The LLC Operating Agreement has numerous provisions related to allocations of income and loss, as well as timing and amounts of distributions to Topco LLC's unit holders. This agreement also includes a provision requiring cash distributions enabling Topco LLC's unit holders to pay their taxes on income passing through from Topco LLC. These tax distributions are computed based on an assumed income tax rate equal to the sum of (i) the maximum combined marginal U.S. federal and state 21 Table of Contents income tax rate applicable to an individual and (ii) the net investment income tax. The assumed income tax rate currently totals 46.7%, which may increase to 54.1% in certain cases where the qualified business income deduction is unavailable. In addition, Topco LLC is subject to entity level taxation in certain states and certain of its subsidiaries are subject to entity level U.S. and foreign income taxes. As a result, the accompanying condensed consolidated statements of operations include income tax expense related to those states and to U.S. and foreign jurisdictions where Topco LLC or any of our subsidiaries are subject to income tax. During the three and six months ended June 30, 2026 and 2025, Topco LLC did not pay any tax distributions to its unit holders. As of June 30, 2026, no amounts for tax distributions had been accrued. 9.Related Party Transactions MLSH 1 is controlled by investment entities affiliated with GTCR. The Company's General Counsel is an officer of MLSH 1 and MLSH 2. Payable to Related Parties Pursuant to the Tax Receivable Agreement We are a party to a TRA with MLSH 1 and MLSH 2. The TRA provides for the payment by us to MLSH 1 and MLSH 2, collectively, of 85% of the amount of certain tax benefits, if any, that we actually realize, or in some circumstances are deemed to realize, as a result of the Organizational Transactions, the IPO and any subsequent purchases or exchanges of LLC Units. The Company expects to benefit from the remaining 15% of any cash tax savings that it realizes. We recognize the amount of TRA payments expected to be paid within the next 12 months and classify this amount as current. This determination is based on our taxable income for the year ended December 31, 2025. As of June 30, 2026, there was no current liability under the TRA. The estimation of liability under the TRA is by its nature imprecise and subject to significant assumptions regarding the amount, character, and timing of the taxable income in the future. If the Company concludes in a future period that the tax benefits are more likely than not to be realized and releases its valuation allowance, the corresponding TRA liability amounts may be considered probable at that time and recorded on the consolidated balance sheet and within earnings. There have been no changes to our position set forth in the 2025 Form 10-K. The impact of any activity for the year ending December 31, 2026, including any LLC Unit exchanges or changes to our estimated U.S. federal, state and local income tax rates, will be included in the Company's Annual Report on Form 10-K for the year ending December 31, 2026 when such impacts are determinable. As of June 30, 2026 and December 31, 2025, there were no liabilities outstanding under the TRA. During the three and six months ended June 30, 2026 and 2025, no payments were made to MLSH 1 or MLSH 2 pursuant to the TRA. Topco LLC Operating Agreement MLSH 1 is party to the LLC Operating Agreement put in place at the date of the Organizational Transactions. This agreement includes a provision requiring cash distributions enabling Topco LLC's unit holders to pay their taxes on income passing through from Topco LLC. During the three and six months ended June 30, 2026 and 2025, no such cash distributions were made for tax liabilities to MLSH 1 under this agreement. 10.Segments The Company's financial performance is reported in two segments. A description of each segment follows: •TriLink: focuses on the development, manufacturing and sale of highly modified nucleic acids and enzymes to support the needs of customers' research, therapeutic and vaccine programs. In addition to catalog and custom products, the business provides contract development and manufacturing ("CDMO") services, including process development, scale-up, and GMP production for clinical and commercial applications. This segment also provides research products for labeling and detecting proteins in cells and tissue samples. •Cygnus: focuses on the development, manufacturing and sale of host cell protein, bioprocess impurity detection, viral clearance prediction kits and associated products. This segment also provides services for custom antibody development, assay development, antibody affinity extraction and mass spectrometry that are utilized by our customers in their biologic drug manufacturing spectrum. 22 Table of Contents The Company defines adjusted earnings before interest, tax, depreciation and amortization ("Adjusted EBITDA") as net loss before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that the Company does not consider in its evaluation of ongoing operating performance from period to period, and has determined that Adjusted EBITDA is the profit or loss measure that the Company's chief operating decision maker ("CODM") uses to make resource allocation decisions and evaluate segment performance. Adjusted EBITDA assists management in comparing the segment performance on a consistent basis for purposes of business decision-making by removing the impact of certain items that management believes do not directly reflect the Company's core operations and, therefore, are not included in measuring segment performance. The CODM reviews segment performance along with forecasts and other non-financial information in our annual budgeting process. Corporate costs are managed on a standalone basis and are not allocated to segments. The following schedules include revenue, expenses, and Adjusted EBITDA for each of the Company's reportable segments for the periods presented (in thousands): Three Months Ended June 30, 2026 TriLink Cygnus Total Revenue $ 34,669 $ 16,773 $ 51,442 Less: Cost of revenue (1) 18,320 2,823 Selling and marketing (1) 4,016 821 General and administrative (1) 2,948 1,379 Research and development (1) 2,304 375 Other segment items (2) 52 - Adjusted EBITDA for reportable segments 7,029 11,375 $ 18,404 Reconciliation of total reportable segments' Adjusted EBITDA to loss before income taxes Corporate costs (9,730) Amortization (6,469) Depreciation (5,313) Interest expense (4,809) Interest income 1,159 Other adjustments: Acquisition integration costs (218) Stock-based compensation (10,205) Loss on extinguishment of debt (3,011) Restructuring costs (3) 33 Other (4) (1,643) Loss before income taxes (21,802) Income tax benefit 171 Net loss $ (21,631) 23 Table of Contents Six Months Ended June 30, 2026 TriLink Cygnus Total Revenue $ 82,145 $ 35,134 $ 117,279 Less: Cost of revenue (1) 39,022 4,985 Selling and marketing (1) 7,708 1,610 General and administrative (1) 6,159 2,747 Research and development (1) 4,825 858 Other segment items (2) 143 1 Adjusted EBITDA for reportable segments 24,288 24,933 $ 49,221 Reconciliation of total reportable segments' Adjusted EBITDA to loss before income taxes Corporate costs (20,220) Amortization (12,941) Depreciation (10,213) Interest expense (10,558) Interest income 3,032 Other adjustments: Acquisition integration costs (449) Stock-based compensation (16,948) Loss on extinguishment of debt (3,413) Restructuring costs (3) (3,077) Other (4) (2,764) Loss before income taxes (28,330) Income tax benefit 322 Net loss $ (28,008) 24 Table of Contents Three Months Ended June 30, 2025 TriLink Cygnus Total Revenue $ 31,085 $ 16,312 $ 47,397 Less: Cost of revenue (1) 24,407 3,002 Selling and marketing (1) 6,367 745 General and administrative (1) 5,179 1,186 Research and development (1) 2,496 516 Other segment items (2) (94) 3 Adjusted EBITDA for reportable segments (7,270) 10,860 $ 3,590 Reconciliation of total reportable segments' Adjusted EBITDA to loss before income taxes Corporate costs (14,000) Amortization (7,200) Depreciation (5,957) Interest expense (6,815) Interest income 3,030 Other adjustments: Acquisition integration costs (831) Stock-based compensation (6,789) Merger and acquisition related expenses (92) Acquisition related tax adjustment (4,153) Executive leadership transition costs (2,007) Goodwill impairment (30,449) Property and equipment impairment (1,052) Other (4) (1,400) Loss before income taxes (74,125) Income tax benefit 4,288 Net loss $ (69,837) 25 Table of Contents Six Months Ended June 30, 2025 TriLink Cygnus Total Revenue $ 59,835 $ 34,412 $ 94,247 Less: Cost of revenue (1) 49,229 5,803 Selling and marketing (1) 12,135 1,575 General and administrative (1) 9,694 2,399 Research and development (1) 4,994 1,101 Other segment items (2) (47) 3 Adjusted EBITDA for reportable segments (16,170) 23,531 $ 7,361 Reconciliation of total reportable segments' Adjusted EBITDA to loss before income taxes Corporate costs (28,320) Amortization (14,230) Depreciation (11,650) Interest expense (13,593) Interest income 6,255 Other adjustments: Acquisition integration costs (1,598) Stock-based compensation (17,192) Merger and acquisition related expenses (1,270) Acquisition related tax adjustment (4,082) Executive transition costs (2,007) Goodwill impairment (42,884) Property and equipment impairment (1,052) Other (4) (2,554) Loss before income taxes (126,816) Income tax benefit $ 4,126 Net loss $ (122,690) ___________________ (1)Expenses are adjusted to remove the impact of certain items, including interest, taxes, depreciation and amortization, certain non-cash items and other adjustments. Management believes these do not directly reflect our core operations, and, therefore, are not included in measuring segment performance. (2)Other segment items for each reportable segment include realized and unrealized losses on foreign exchange transactions. (3)For the three and six months ended June 30, 2026, stock-based compensation benefit was nominal and $0.2 million, respectively, related to forfeited stock awards in connection with the 2025 Corporate Realignment Plan is included in the stock-based compensation line item. (4)For the three and six months ended June 30, 2026 and for the three and six months ended June 30, 2025, refers to severance expense, inventory step-up charges in connection with the acquisition of Alphazyme, non-recurring legal costs, change in the estimated fair value of contingent consideration related to completed acquisitions, and other non-recurring costs that are deemed to be outside of the ordinary course of business. There was immaterial intersegment revenue during the three and six months ended June 30, 2026 and 2025. The Company does not allocate assets to its reportable segments as they are not included in the review performed by the CODM for purposes of assessing segment performance and allocating resources. 26 Table of Contents Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following discussion and analysis of financial condition and results of operations together with our condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC. This discussion and analysis reflects our historical results of operations and financial position and contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025. Please also see the section entitled "Special Note Regarding Forward-Looking Statements." Unless otherwise noted or the context otherwise requires, references in this Quarterly Report on Form 10-Q to "we," "us" or "our" refer to Maravai LifeSciences Holdings, Inc. and its subsidiaries. Overview We are a life sciences company that provides products and services supporting the development and manufacture of drug therapies, diagnostics, vaccines and cell and gene therapies. Our customers include biopharmaceutical companies, emerging biopharmaceutical, life sciences research companies, academic research institutions and diagnostics companies. Our product offerings support key phases of biopharmaceutical development and manufacturing and include complex nucleic acids and enzymes for therapeutic and diagnostic applications, and immunoassay, qPCR and mass spectrometry-based products and services to detect impurities during the production of biopharmaceutical products. We manage and evaluate our operations through two reportable segments: TriLink and Cygnus. Our primary end customers are biopharmaceutical companies who are pursuing novel research and product development programs across a range of therapeutic modalities. We also serve government, academic and biotechnology institutions. As of June 30, 2026, we employed a team of 415 full-time employees, approximately 26% of whom have advanced degrees. We primarily utilize a direct sales model in North America. International sales, primarily in Europe and the Asia Pacific-region, are generated through a combination of direct sales and third-party distributors. The percentage of our total revenue derived from customers in North America was 60.8% and 57.1% for the three and six months ended June 30, 2026, respectively. The percentage of our total revenue derived from customers in North America was 64.6% and 63.6% for the three and six months ended June 30, 2025, respectively. We generated revenue of $51.4 million and $117.3 million for the three and six months ended June 30, 2026 and $47.4 million and $94.2 million for the three and six months ended June 30, 2025, respectively. Revenue by reportable segment was as follows: TriLink: $34.7 million and $82.1 million for the three and six months ended June 30, 2026, respectively, and $31.1 million and $59.8 million for the three and six months ended June 30, 2025, respectively. Cygnus: $16.8 million and $35.1 million for the three and six months ended June 30, 2026, respectively, and $16.3 million and $34.4 million for the three and six months ended June 30, 2025, respectively. We continue to focus resources on supporting our core business segments while pursuing opportunities to expand our customer base domestically and internationally. Selling, general and administrative expenses were $32.1 million and $61.2 million for the three and six months ended June 30, 2026, respectively, and $38.7 million and $78.3 million for the three and six months ended June 30, 2025, respectively. Our research and development efforts are focused on developing new products, technologies and services to meet our customers' needs. Research and development expenses were $3.7 million and $7.6 million for the three and six months ended June 30, 2026, and $4.9 million and $9.8 million for the three and six months ended June 30, 2025, respectively. We intend to continue investing in research and development to support our customers' demand for innovation. Debt Refinancing On June 2, 2026, we entered into a new credit agreement, which provides for a $150.0 million term loan facility and a $30.0 million revolving credit facility, each maturing on June 2, 2032. In connection with the new credit agreement, we repaid all amounts outstanding under our prior credit agreement and terminated the prior term loan facility and revolving credit facility, including the related guarantees and security interests. Borrowings under the new credit agreement bear interest at variable rates 27 Table of Contents based on Term SOFR or an alternate base rate, plus an applicable margin. Refer to the "Liquidity and Capital Resources" section for additional discussion of our debt financing arrangements. Trends and Uncertainties While revenue attributable to high-volume orders of our proprietary CleanCap® analogs for commercial phase COVID-19 vaccine programs returned in the first quarter of 2026, representing $14.3 million in revenue for the three months ended March 31, 2026, we did not recognize any revenue attributable to high-volume CleanCap orders in the second quarter of 2026 and do not anticipate any further high-volume CleanCap orders for commercial phase COVID-19 vaccine programs for the remainder of the year ending December 31, 2026. How We Assess Our Business We consider a variety of financial and operating measures in assessing the performance of our business. The key measures we use to determine how our business is performing are revenue and Adjusted EBITDA. Adjusted EBITDA is a non-GAAP financial performance measure that we define as net loss adjusted for interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider in our evaluation of ongoing operating performance from period to period. Management uses Adjusted EBITDA to evaluate the financial performance of our business and the effectiveness of our business strategies. We present Adjusted EBITDA because we believe this performance measure is frequently used by analysts, investors and other interested parties to evaluate companies in our industry and it facilitates comparisons of performance on a consistent basis across reporting periods. Adjusted EBITDA is a non-GAAP measure and, therefore, may have limitations as an analytical tool, so it should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments in the presentation of Adjusted EBITDA. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations that Adjusted EBITDA does not reflect include: •all expenditures or future requirements for capital expenditures or contractual commitments; •changes in our working capital needs; •provision for income taxes, which may be a necessary element of our costs and ability to operate; •the costs of replacing the assets being depreciated, which will often have to be replaced in the future; and •the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations. In addition, because Adjusted EBITDA is not a measure of financial performance under GAAP, it may not be comparable to similarly titled measures used by other companies in our industry or across different industries. Components of Results of Operations Revenue Our revenue consists primarily of product revenue and, to a much lesser extent, service revenue. We generated total consolidated revenue of $51.4 million and $117.3 million for the three and six months ended June 30, 2026, and $47.4 million and $94.2 million for the three and six months ended June 30, 2025, respectively, through the following segments: (i) TriLink and (ii) Cygnus. TriLink Segment Our TriLink segment focuses on the development, manufacturing and sale of highly modified nucleic acids products to support the needs of customers' research, therapeutic and vaccine programs. In addition to catalog and custom products, the business provides CDMO services, including process development, scale-up, and GMP production of nucleic acids for clinical applications. This segment also provides research products for oligonucleotide synthesis, modification, labeling and purification. 28 Table of Contents Cygnus Segment Our Cygnus segment focuses on the development, manufacturing and sale of biologics safety and impurity tests and assay development services that are utilized by our customers in their biologic drug manufacturing activities. Cost of Revenue Cost of revenue associated with our products primarily consists of manufacturing related costs incurred in the production process, including personnel and related costs, stock-based compensation expense, costs of materials, labor and overhead, packaging and delivery costs and allocated costs, including facilities, information technology, depreciation and amortization of intangibles. Cost of revenue also includes adjustments for excess, obsolete or expired inventory, and idle capacity. Cost of revenue associated with our services primarily consists of personnel and related costs, stock-based compensation expense, cost of materials and allocated costs, including facilities and information technology costs. We expect cost of revenue to remain below prior-year levels as a percentage of revenue as we continue to realize the benefits of our restructuring actions. Operating Expenses Selling, General and Administrative Our selling, general and administrative expenses primarily consist of salaries, benefits and stock-based compensation expense for our employees in our commercial sales functions, marketing, executive, accounting and finance, legal and human resource functions as well as travel expenses, professional services fees, such as consulting, audit, tax and legal fees, general corporate costs and allocated costs, including facilities, information technology and amortization of intangibles. We expect our selling, general and administrative expenses to remain below prior-year levels as we continue to realize the benefits of our restructuring actions, while remaining relatively stable for the remainder of the fiscal year. Research and Development Research and development expenses primarily consist of salaries, benefits, stock-based compensation expense for employees engaged in research and development of products and services, outside contracted services, cost of supplies, allocated facilities costs, and information technology costs. We expense all research and development costs in the period in which they are incurred. We expect our research and development expenses to remain below prior-year levels as we continue to realize the benefits of our restructuring actions, while remaining relatively stable for the remainder of the fiscal year. Goodwill Impairment Goodwill impairment is recorded in connection with the impairment testing of our goodwill and is performed at least annually and more frequently if changes in facts and circumstances indicate that the fair value of our reporting units may be less than the carrying amount. Restructuring Restructuring costs primarily consist of severance and other employee-related costs, asset impairments, and professional fees. Other Income (Expense) Interest Expense Interest expense consists of interest costs and the related amortization of the debt discount and deferred issuance costs on our outstanding debt, and interest costs on our finance lease liabilities. Interest Income Interest income consists of interest earned on our cash balances and short-term investments in money market funds held at financial institutions. 29 Table of Contents Other Income (Expense) Other income (expense) primarily consists of adjustments to the indemnification asset recorded in connection with the acquisition of MyChem, LLC ("MyChem"), which was completed in January 2022, and realized and unrealized gains and losses on foreign exchange transactions. Income Tax Expense (Benefit) We are subject to U.S. federal, state and local income taxes with respect to our allocable share of any taxable income of Topco LLC and will be taxed at the prevailing corporate tax rates. Non-Controlling Interests Non-controlling interests represent the portion of profit or loss, net assets and comprehensive income or loss of our consolidated subsidiaries that is not allocable to the Company based on our percentage of ownership of such entities. Income or loss attributed to the non-controlling interests is based on the LLC Units outstanding during the period and is presented on the condensed consolidated statements of operations. As of June 30, 2026, we held approximately 57.4% of the outstanding LLC Units, and MLSH 1 held approximately 42.6% of the outstanding LLC Units. Results of Operations The results of operations presented below should be reviewed in conjunction with the condensed consolidated financial statements and notes included elsewhere in this Quarterly Report on Form 10-Q. For information with respect to recent accounting pronouncements that are of significance or potential significance to us, see Note 1 to the condensed consolidated financial statements contained in Part I, Item 1 of this Quarterly Report on Form 10-Q. Three Months Ended June 30, 2026 2025 Year-Over-Year Change (in thousands, except per share amounts) Revenue $ 51,442 $ 47,397 8.5 % Cost of revenue (1) 30,792 39,629 (22.3) % Gross profit 20,650 7,768 165.8 % Operating expenses: Selling, general and administrative (1) 32,070 38,715 (17.2) % Research and development (1) 3,702 4,882 (24.2) % Goodwill impairment - 30,449 * Restructuring (1) (33) - * Total operating expenses 35,739 74,046 (51.7) % Loss from operations (15,089) (66,278) (77.2) % Other expense, net (6,713) (7,847) (14.5) % Loss before income taxes (21,802) (74,125) (70.6) % Income tax benefit (171) (4,288) (96.0) % Net loss (21,631) (69,837) (69.0) % Net loss attributable to non-controlling interests (9,215) (30,246) (69.5) % Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (12,416) $ (39,591) (68.6) % Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted $ (0.08) $ (0.27) Weighted average number of Class A common shares outstanding, basic and diluted 147,996 144,236 Adjusted EBITDA (Non-GAAP financial measure) $ 8,674 $ (10,410) 30 Table of Contents Six Months Ended June 30, 2026 2025 Year-Over-Year Change (in thousands, except per share amounts) Revenue $ 117,279 $ 94,247 24.4 % Cost of revenue (1) 62,928 78,754 (20.1) % Gross profit 54,351 15,493 250.8 % Operating expenses: Selling, general and administrative (1) 61,162 78,279 (21.9) % Research and development (1) 7,591 9,770 (22.3) % Goodwill impairment - 42,884 * Restructuring (1) 2,845 - * Total operating expenses 71,598 130,933 (45.3) % Loss from operations (17,247) (115,440) (85.1) % Other expense, net (11,083) (11,376) (2.6) % Loss before income taxes (28,330) (126,816) (77.7) % Income tax benefit (322) (4,126) (92.2) % Net loss (28,008) (122,690) (77.2) % Net loss attributable to non-controlling interests (11,859) (53,154) (77.7) % Net loss attributable to Maravai LifeSciences Holdings, Inc. $ (16,149) $ (69,536) (76.8) % Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic and diluted $ (0.11) $ (0.48) Weighted average number of Class A common shares outstanding, basic and diluted 147,215 143,833 Adjusted EBITDA (Non-GAAP financial measure) $ 29,001 $ (20,959) ____________________ * Not meaningful (1)Includes stock-based compensation expense (benefit) as follows (in thousands, except percentages): Three Months Ended June 30, 2026 2025 Year-Over-Year Change Cost of revenue $ 1,011 $ 1,847 (45.3) % Selling, general and administrative 8,525 3,697 130.6 % Research and development 683 1,245 (45.1) % Restructuring (14) - * Total stock-based compensation expense $ 10,205 $ 6,789 50.3 % Six Months Ended June 30, 2026 2025 Year-Over-Year Change Cost of revenue $ 1,925 $ 3,889 (50.5) % Selling, general and administrative 14,030 10,843 29.4 % Research and development 1,239 2,460 (49.6) % Restructuring (246) - * Total stock-based compensation expense $ 16,948 $ 17,192 (1.4) % 31 Table of Contents Revenue Consolidated revenue by segment was as follows for the periods presented (in thousands, except percentages): Three Months Ended June 30, Percentage of Revenue 2026 2025 Year-Over-Year Change 2026 2025 TriLink $ 34,669 $ 31,085 11.5 % 67.4 % 65.6 % Cygnus 16,773 16,312 2.8 % 32.6 % 34.4 % Total revenue $ 51,442 $ 47,397 8.5 % 100.0 % 100.0 % Six Months Ended June 30, Percentage of Revenue 2026 2025 Year-Over-Year Change 2026 2025 TriLink $ 82,145 $ 59,835 37.3 % 70.0 % 63.5 % Cygnus 35,134 34,412 2.1 % 30.0 % 36.5 % Total revenue $ 117,279 $ 94,247 24.4 % 100.0 % 100.0 % Comparison of Three Months Ended June 30, 2026 and 2025 Total revenue increased 8.5% from the three months ended June 30, 2025 compared to the three months ended June 30, 2026. TriLink revenue increased 11.5% from the three months ended June 30, 2025 to the three months ended June 30, 2026. The increase in TriLink revenue was primarily driven by increased demand for research use only (RUO) raw materials used in drug discovery (Discovery mRNA) and GMP products used in clinical trials (GMP consumables). Cygnus revenue increased by 2.8% from the three months ended June 30, 2025 to the three months ended June 30, 2026. The increase was driven by increased demand for Host Cell Protein (HCP) and ELISA kits and strength in China due to distributor ordering timing. Comparison of Six Months Ended June 30, 2026 and 2025 Total revenue increased 24.4% from the six months ended June 30, 2025 compared to the six months ended June 30, 2026. TriLink revenue increased by 37.3% comparing the six months ended June 30, 2025 to the six months ended June 30, 2026. The increase in TriLink revenue was primarily driven by $14.3 million of high-volume CleanCap orders for commercial phase COVID vaccine programs during the first quarter of 2026. Excluding COVID CleanCap revenue, TriLink base revenue grew 13.4% year-over-year with increased demand for both Discovery mRNA and GMP consumables. Cygnus revenue increased by 2.1% from the six months ended June 30, 2025 to the six months ended June 30, 2026. The increase was driven by demand for HCP, ELISA and DNA detection kits. Gross Profit Gross profit was as follows for the periods presented (in thousands, except percentages): Three Months Ended June 30, Percentage of Revenue 2026 2025 Year-Over-Year Change 2026 2025 Revenue $ 51,442 $ 47,397 8.5 % 100.0 % 100.0 % Cost of revenue 30,792 39,629 (22.3) % 59.9 % 83.6 % Gross profit $ 20,650 $ 7,768 165.8 % 40.1 % 16.4 % Six Months Ended June 30, Percentage of Revenue 2026 2025 Year-Over-Year Change 2026 2025 Revenue $ 117,279 $ 94,247 24.4 % 100.0 % 100.0 % Cost of revenue 62,928 78,754 (20.1) % 53.7 % 83.6 % Gross profit $ 54,351 $ 15,493 250.8 % 46.3 % 16.4 % 32 Table of Contents Comparison of Three Months Ended June 30, 2026 and 2025 Cost of revenue decreased by 22.3% from the three months ended June 30, 2025 to the three months ended June 30, 2026. The decrease was driven by a $3.9 million decrease in direct product costs primarily from higher excess and obsolete charges for excess raw materials, inventory write-offs and yield losses in the prior year. There was also a $2.3 million decrease in personnel expenses, a $0.5 million decrease in supplies, materials and external services, a $0.7 million decrease in stock-based compensation, a $0.7 million decrease in amortization, and a $0.7 million decrease in facilities costs. These decreases were primarily driven by the 2025 Corporate Realignment Plan. Gross profit margin increased by 2,370 basis points from the three months ended June 30, 2025 to the three months ended June 30, 2026. The increase in gross profit margin as a percentage of sales was primarily attributable to product mix and the decrease in cost of revenue driven by the 2025 Corporate Realignment Plan. Comparison of Six Months Ended June 30, 2026 and 2025 Cost of revenue decreased by 20.1% from the six months ended June 30, 2025 to the six months ended June 30, 2026. The decrease was driven by a $4.0 million decrease in direct product costs primarily from higher excess and obsolete charges for excess raw materials, inventory write-offs and yield losses in the prior year. There was also a $5.6 million decrease in personnel expenses, a $1.7 million decrease in stock-based compensation expense,a $1.6 million decrease in facilities costs, a $1.3 million decrease in supplies, materials and external services, a $1.2 million decrease in amortization, and a $0.4 million decrease in depreciation. These decreases were primarily driven by the 2025 Corporate Realignment Plan. Gross profit margin increased by 2,990 basis points from the six months ended June 30, 2025 to the six months ended June 30, 2026. The increase in gross profit margin as a percentage of sales was primarily attributable to product mix and the decrease in cost of revenue driven by the 2025 Corporate Realignment Plan. Operating Expenses Operating expenses included the following for the periods presented (in thousands, except percentages): Three Months Ended June 30, Percentage of Revenue 2026 2025 Year-Over-Year Change 2026 2025 Selling, general and administrative $ 32,070 $ 38,715 (17.2) % 62.4 % 81.7 % Research and development 3,702 4,882 (24.2) % 7.2 % 10.3 % Goodwill impairment - 30,449 * - % 64.2 % Restructuring (33) - * (0.1) % - % Total operating expenses $ 35,739 $ 74,046 (51.7) % 69.5 % 156.2 % Six Months Ended June 30, Percentage of Revenue 2026 2025 Year-Over-Year Change 2026 2025 Selling, general and administrative $ 61,162 $ 78,279 (21.9) % 52.1 % 83.0 % Research and development 7,591 9,770 (22.3) % 6.5 % 10.4 % Goodwill impairment - 42,884 * - % 45.5 % Restructuring 2,845 - * 2.4 % - % Total operating expenses $ 71,598 $ 130,933 (45.3) % 61.0 % 138.9 % ____________________ *Not meaningful Selling, General and Administrative Comparison of Three Months Ended June 30, 2026 and 2025 Selling, general and administrative expenses decreased by 17.2% from the three months ended June 30, 2025 to the three months ended June 30, 2026. The decrease was primarily due to a $4.3 million decrease in personnel expenses, a $2.5 million decrease in professional services fees, a $1.5 million decrease in marketing expenses, a $0.9 million decrease in facilities costs, a $0.6 million decrease in depreciation, and a $0.5 million decrease in miscellaneous expenses. These decreases were primarily 33 Table of Contents driven by the 2025 Corporate Realignment Plan. The decreases were partially offset by an increase of $4.8 million in stock-based compensation expense due to performance stock units granted in the first quarter of 2026, and the three months ended June 30, 2025 included a $1.1 million impairment charge related to property and equipment, which did not recur in the current period. Comparison of Six Months Ended June 30, 2026 and 2025 Selling, general and administrative expenses decreased by 21.9% from the six months ended June 30, 2025 to the six months ended June 30, 2026. The decrease was primarily due to a $8.6 million decrease in personnel expenses, a $4.6 million decrease in professional services fees, a $2.3 million decrease in marketing expenses, a $1.8 million decrease in facilities costs, a $1.2 million decrease in depreciation, and a $0.7 million decrease in other miscellaneous expenses. These decreases were primarily driven by the 2025 Corporate Realignment Plan. The decreases were partially offset by an increase of $3.2 million in stock-based compensation expense due to performance stock units granted in the first quarter of 2026, and the six months ended June 30, 2025 included a $1.1 million impairment charge related to property and equipment recorded, which did not recur in the current period. Research and Development Comparison of Three Months Ended June 30, 2026 and 2025 Research and development expenses decreased by 24.2% from the three months ended June 30, 2025 to the three months ended June 30, 2026. The decrease was primarily driven by a $0.5 million decrease in stock-based compensation expense, a $0.3 million decrease in personnel expenses, a $0.2 million decrease in supplies and materials, and a $0.2 million decrease in services and other expenses. These decreases were primarily driven by the 2025 Corporate Realignment Plan. Comparison of Six Months Ended June 30, 2026 and 2025 Research and development expenses decreased by 22.3% from the six months ended June 30, 2025 to the six months ended June 30, 2026. The decrease was primarily driven by a $1.1 million decrease in stock-based compensation expense, a $0.6 million decrease in personnel expenses, and a $0.5 million decrease in supplies and materials. These decreases were primarily driven by the 2025 Corporate Realignment Plan. This was partially offset by an increase of $0.3 million in facilities expenses. Goodwill Impairment Comparison of Three Months Ended June 30, 2026 and 2025 During the three months ended June 30, 2025, we recorded goodwill impairment of $30.4 million for the Alphazyme reporting unit within our TriLink segment. During the three months ended June 30, 2026, no goodwill impairment was recorded. Comparison of Six Months Ended June 30, 2026 and 2025 During the six months ended June 30, 2025, we recorded goodwill impairment of $42.9 million within our TriLink segment. During the six months ended June 30, 2026, no goodwill impairment was recorded. Restructuring Restructuring costs for the six months ended June 30, 2026 were attributable to the 2025 Corporate Realignment Plan. These costs included severance and other employee-related benefit of ($0.4 million), non-employee contract costs of $2.0 million, asset impairments of $0.4 million, and professional fees of $0.9 million. 34 Table of Contents Other Income (Expense) Other income (expense) included the following for the periods presented (in thousands, except percentages): Three Months Ended June 30, Percentage of Revenue 2026 2025 Year-Over-Year Change 2026 2025 Interest expense $ (4,809) $ (6,815) (29.4) % (9.3) % (14.4) % Interest income 1,159 3,030 (61.7) % 2.3 % 6.4 % Loss on extinguishment of debt (3,011) - * (5.9) % - % Other expense (52) (4,062) (98.7) % (0.1) % (8.6) % Total other expense $ (6,713) $ (7,847) (14.5) % (13.0) % (16.6) % Six Months Ended June 30, Percentage of Revenue 2026 2025 Year-Over-Year Change 2026 2025 Interest expense $ (10,558) $ (13,593) (22.3) % (9.0) % (14.4) % Interest income 3,032 6,255 (51.5) % 2.6 % 6.6 % Loss on extinguishment of debt (3,413) - * (2.9) % - % Other expense (144) (4,038) (96.4) % (0.1) % (4.3) % Total other expense $ (11,083) $ (11,376) (2.6) % (9.4) % (12.1) % ____________________ *Not meaningful Comparison of Three Months Ended June 30, 2026 and 2025 Total other expense decreased 14.5% from the three months ended June 30, 2025 compared to the three months ended June 30, 2026. This was due to a $2.0 million decrease in interest expense, which was primarily due to the repayment of all amounts outstanding under our prior credit agreement, and the termination of the prior credit agreement, including the related term loan facility and revolving credit facility, as part of the June 2026 debt refinancing, and a $4.2 million decrease in other expense as the prior year had adjustments to the indemnification asset recorded in connection with the acquisition of MyChem partially offset by immaterial foreign exchange gains and losses. In addition, there was a $1.9 million decrease in interest income earned on our short-term investments in money market funds, which was used for the debt repayment, and a $3.0 million loss on debt extinguishment recorded in the three months ended June 30, 2026 in connection with the debt refinancing. Comparison of Six Months Ended June 30, 2026 and 2025 Total other expense decreased 2.6% from the six months ended June 30, 2025 compared to the six months ended June 30, 2026. The decrease was driven by a $3.0 million decrease in interest expense, which was primarily due to the voluntary prepayment of principal on the Term Loan in February 2026, the repayment of all amounts outstanding under our prior credit agreement, and the termination of the prior credit agreement and the related term loan facility and revolving credit facility as part of the June 2026 debt refinancing, and the $3.9 million decrease in other expense, which includes $4.1 million from prior year adjustments to the indemnification asset recorded in connection with the acquisition of MyChem, partially offset by immaterial foreign exchange gains and losses. In addition, there was a $3.2 million decrease in interest income earned on our short-term investments in money market funds, which was used for the debt repayment, and a $3.4 million loss on debt extinguishment recorded in the six months ended June 30, 2026. Segment Information Management has determined that adjusted earnings before interest, tax, depreciation and amortization is the profit or loss measure used to make resource allocation decisions and evaluate segment performance. Adjusted EBITDA assists management in comparing the segment performance on a consistent basis for purposes of business decision-making by removing the impact of certain items that management believes do not directly reflect the Company's core operations and, therefore, are not included in measuring segment performance. Our CODM reviews segment performance along with forecasts and other non-financial information in our annual budgeting process. We define Adjusted EBITDA as net loss before interest, taxes, depreciation and amortization, certain non-cash items and other adjustments that we do not consider in our evaluation of ongoing operating performance from period to period. Corporate costs are managed on a standalone basis and are not allocated to segments. 35 Table of Contents We do not allocate assets to our reportable segments as they are not included in the review performed by our CODM for purposes of assessing segment performance and allocating resources. As of June 30, ...

View stock analysis, news, and events for Aersale Corporation